Table I.
Characteristics of patients with recurrent cutaneous squamous cell carcinoma (cSCC) (n = 25; 3.2% of 774), recurrent cSCC tumours (n = 25; 2.2% of 1,131), patients with metastatic cSCC (n = 48; 6.2% of 774) and metastatic cSCC tumours (n = 48; 4.2% of 1,131)
| Recurrent tumour | Not recurrent tumour | Metastatic tumour | Not metastatic tumour | |||
|---|---|---|---|---|---|---|
| n (%) | n (%) | p-value | n (%) | n (%) | p-value | |
| Patients | n= 25 | n = 749 | n = 48 | n = 726 | ||
| Sex | 0.840 | 0.103 | ||||
| Men | 12 (48.0) | 382 (51.0) | 30 (62.5) | 364 (50.1) | ||
| Women | 13 (52.0) | 367 (49.0) | 18 (37.5) | 362 (49.9) | ||
| Age | 0.865 | 0.151 | ||||
| < 60 years | 0 (0) | 35 (4.7) | 4 (8.3) | 31 (4.3) | ||
| 60-69 years | 2 (8.0) | 82 (11.0) | 9 (18.8) | 75 (10.3) | ||
| 70-79 years | 10 (40.0) | 228 (30.4) | 12 (25.0) | 226 (31.1) | ||
| 80-89 years | 10 (40.0) | 313 (41.8) | 16 (33.3) | 307 (42.3) | ||
| ≥ 90 years | 3 (12.0) | 91 (12.1) | 7 (14.6) | 87 (12.0) | ||
| Immunosuppression | 1.000 | 1.000 | ||||
| No | 23 (92.0) | 670 (89.5) | 43 (89.6) | 650 (89.5) | ||
| Yes | 2 (8.0) | 79 (10.5) | 5 (10.4) | 76 (10.5) | ||
| Actinic keratosis/Bowen’s disease | 0.165 | < 0.001 | ||||
| No | 10 (40.0) | 205 (27.4) | 27 (56.3) | 188 (25.9) | ||
| Yes | 15 (60.0) | 544 (72.6) | 21 (43.8) | 538 (74.1) | ||
| Basal cell carcinoma | 0.837 | 0.049 | ||||
| No | 14 (56.0) | 444 (59.3) | 35 (72.9) | 423 (58.3) | ||
| Yes | 11 (44.0) | 305 (40.7) | 13 (27.1) | 303 (41.7) | ||
| Cutaneous melanoma | 0.673 | 0.357 | ||||
| No | 23 (92.0) | 701 (93.6) | 47 (97.9) | 677 (93.3) | ||
| Yes | 2 (8.0) | 48 (6.4) | 1 (2.1) | 49 (6.7) | ||
| Tumours | n = 25 | n = 1,106 | n = 48 | n = 1,083 | ||
| Tumour location | 0.271 | < 0.001 | ||||
| Lip | 2 (8.0) | 50 (4.5) | 3 (6.3) | 49 (4.5) | ||
| Eyelid | 0 (0) | 11 (1.0) | 1 (2.1) | 10 (0.9) | ||
| Ear | 1 (4.0) | 105 (9.5) | 4 (8.3) | 102 (9.4) | ||
| Face | 9 (36.0) | 555 (50.2) | 17 (35.4) | 547 (50.5) | ||
| Scalp and neck | 4 (16.0) | 87 (7.9) | 5 (10.4) | 86 (7.9) | ||
| Trunk | 2 (8.0) | 59 (5.3) | 1 (2.1) | 60 (5.5) | ||
| Upper extremity | 3 (12.0) | 133 (12.0) | 1 (2.1) | 135 (12.5) | ||
| Lower extremity | 2 (8.0) | 66 (6.0) | 2 (4.2) | 66 (6.1) | ||
| Anogenital area | 1 (4.0) | 30 (2.7) | 9 (18.8) | 22 (2.0) | ||
| Oral cavity | 1 (4.0) | 10 (0.9) | 5 (10.4) | 6 (0.6) | ||
| Tumour differentiation | 0.130 | < 0.001 | ||||
| Well | 9 (36.0) | 512 (46.3) | 6 (12.5) | 515 (47.6) | ||
| Moderately | 9 (36.0) | 441 (39.9) | 27 (56.3) | 423 (39.1) | ||
| Poorly | 5 (20.0) | 84 (7.6) | 14 (29.2) | 75 (6.9) | ||
| Unknown | 2 (8.0) | 69 (6.2) | 1 (2.1) | 70 (6.5) | ||
| Invasion depth | 0.173 | < 0.001 | ||||
| < 1 mm | 1 (4.0) | 44 (4.0) | 0 (0) | 45 (4.2) | ||
| 1.0–2.0 mm | 7 (28.0) | 306 (27.7) | 3 (6.3) | 310 (28.6) | ||
| 2.1.0–4.0 mm | 1 (4.0) | 202 (18.3) | 3 (6.3) | 200 (18.5) | ||
| > 4.0 mm | 5 (20.0) | 107 (9.7) | 15 (31.3) | 97 (9.0) | ||
| Unknown | 11 (44.0) | 447 (40.4) | 27 (56.3) | 431 (39.8) |